Inari Medical, Inc. (NASDAQ: NARI) announced that the results from the PEERLESS trial will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C., on October 29th. The PEERLESS trial is a prospective, randomized controlled trial (RCT) designed to compare the efficacy of Inari's FlowTriever system against catheter-directed thrombolysis in patients with intermediate-risk pulmonary embolism (PE).
The primary endpoint of the PEERLESS trial is a win-ratio analysis of significant clinical outcomes and hospital resource utilization. This rigorous evaluation aims to provide clinicians with data-driven insights into the optimal treatment strategies for patients suffering from PE.
Significance of the PEERLESS Trial
"PEERLESS is the first RCT directly comparing FlowTriever to a historical treatment option for PE and is the first of several RCTs that Inari is bringing to the VTE space," stated Dr. Thomas Tu, Inari’s Chief Medical Officer. He emphasized the importance of high-quality clinical evidence in guiding treatment decisions for both patients and physicians.
About FlowTriever System
The FlowTriever system is a device developed by Inari Medical for the treatment of venous thromboembolism. It is designed to remove large clots from major vessels, aiming to reduce the need for thrombolytic drugs and their associated risks.
Inari Medical's Broader Mission
Inari Medical is dedicated to creating innovative solutions for unmet and underserved health needs. The company focuses on improving patient outcomes through education, clinical research, and program development. Inari's mission is to establish its treatments as the standard of care for venous thromboembolism and other targeted disease states.
